See more : IFGL Refractories Limited (IFGLEXPOR.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Bristol-Myers Squibb Company (0R1F.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bristol-Myers Squibb Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Levi Strauss & Co (LV2B.DE) Income Statement Analysis – Financial Results
- LumiraDx Limited (LMDX) Income Statement Analysis – Financial Results
- Shenzhen Senior Technology Material Co., LTD (300568.SZ) Income Statement Analysis – Financial Results
- Global Entertainment Holdings, Inc. (GBHL) Income Statement Analysis – Financial Results
- Rafina Innovations Inc. (VICA) Income Statement Analysis – Financial Results
Bristol-Myers Squibb Company (0R1F.L)
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.01B | 46.16B | 46.39B | 42.52B | 26.15B | 22.56B | 20.78B | 19.43B | 16.56B | 15.88B | 16.39B | 17.62B |
| Cost of Revenue | 10.52B | 9.78B | 9.94B | 11.77B | 7.90B | 6.41B | 5.87B | 4.95B | 3.83B | 3.78B | 4.84B | 4.55B |
| Gross Profit | 34.49B | 36.38B | 36.45B | 30.75B | 18.25B | 16.15B | 14.91B | 14.48B | 12.74B | 12.10B | 11.54B | 13.07B |
| Gross Profit Ratio | 76.63% | 78.81% | 78.57% | 72.31% | 69.79% | 71.59% | 71.77% | 74.53% | 76.90% | 76.19% | 70.45% | 74.16% |
| Research & Development | 10.21B | 10.32B | 11.35B | 22.58B | 6.15B | 6.33B | 6.47B | 5.01B | 5.92B | 4.53B | 3.73B | 3.90B |
| General & Administrative | 6.28B | 6.40B | 6.35B | 6.63B | 4.34B | 3.85B | 4.01B | 4.03B | 4.01B | 3.98B | 4.07B | 4.14B |
| Selling & Marketing | 1.40B | 1.30B | 1.30B | 990.00M | 633.00M | 672.00M | 740.00M | 789.00M | 825.00M | 734.00M | 855.00M | 797.00M |
| SG&A | 7.68B | 7.70B | 7.66B | 7.62B | 4.97B | 4.52B | 4.75B | 4.82B | 4.83B | 4.72B | 4.92B | 4.93B |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.34B | 27.63B | 27.08B | 36.36B | 12.84B | 10.20B | 9.71B | 8.49B | 10.58B | 9.61B | 8.55B | 10.64B |
| Cost & Expenses | 35.85B | 37.41B | 37.02B | 48.13B | 20.74B | 16.61B | 15.58B | 13.44B | 14.40B | 13.40B | 13.39B | 15.19B |
| Interest Income | 712.00M | 982.00M | 1.25B | 1.26B | 434.00M | 21.00M | 70.00M | 70.00M | 80.00M | 103.00M | 103.00M | 87.00M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.77B | 10.28B | 10.76B | 10.43B | 1.72B | 590.00M | 583.00M | 522.00M | 568.00M | 678.00M | 1.28B | 842.00M |
| EBITDA | 18.42B | 20.16B | 19.33B | 13.82B | 7.80B | 5.87B | 4.56B | 5.71B | 4.44B | 4.15B | 4.18B | 5.29B |
| EBITDA Ratio | 40.93% | 43.68% | 41.67% | 32.51% | 29.83% | 26.01% | 21.96% | 29.39% | 26.78% | 26.11% | 25.51% | 30.02% |
| Operating Income | 8.65B | 9.88B | 8.57B | 3.39B | 6.08B | 5.28B | 3.98B | 5.19B | 3.87B | 3.47B | 2.91B | 4.45B |
| Operating Income Ratio | 19.22% | 21.40% | 18.48% | 7.98% | 23.24% | 23.39% | 19.16% | 26.70% | 23.35% | 21.84% | 17.73% | 25.24% |
| Total Other Income/Expenses | -211.00M | -2.17B | -474.00M | -10.26B | -1.10B | 690.00M | 1.15B | 728.00M | -1.79B | -1.09B | -14.00M | -2.11B |
| Income Before Tax | 8.44B | 7.71B | 8.10B | -6.87B | 4.98B | 5.97B | 5.13B | 5.92B | 2.08B | 2.38B | 2.89B | 2.34B |
| Income Before Tax Ratio | 18.75% | 16.71% | 17.46% | -16.16% | 19.03% | 26.45% | 24.70% | 30.45% | 12.54% | 14.99% | 17.64% | 13.28% |
| Income Tax Expense | 400.00M | 1.37B | 1.08B | 2.12B | 1.52B | 1.02B | 4.16B | 1.41B | 446.00M | 352.00M | 311.00M | 161.00M |
| Net Income | 8.03B | 6.33B | 6.99B | -9.02B | 3.44B | 4.92B | 1.01B | 4.46B | 1.57B | 2.00B | 2.56B | 1.96B |
| Net Income Ratio | 17.83% | 13.71% | 15.08% | -21.20% | 13.15% | 21.81% | 4.85% | 22.94% | 9.45% | 12.62% | 15.64% | 11.12% |
| EPS | 3.86 | 2.95 | 3.12 | -3.99 | 2.01 | 3.01 | 0.61 | 2.65 | 0.93 | 1.20 | 1.54 | 1.16 |
| EPS Diluted | 3.86 | 2.95 | 3.12 | -3.99 | 2.01 | 3.01 | 0.61 | 2.65 | 0.93 | 1.20 | 1.54 | 1.16 |
| Weighted Avg Shares Out | 2.08B | 2.14B | 2.24B | 2.26B | 1.71B | 1.63B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B |
| Weighted Avg Shares Out (Dil) | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B |
Source: https://incomestatements.info
Category: Stock Reports